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New generation of Microbicides that are formulated using
anti-retroviral drugs have reviewed hopes of getting a tool
that would prevent HIV infection before 2015. Since ARVs
have shown to prolong lives of people infected with HIV;
being positive that these could be turned into effective
microbicides.
Optimistic about the second generation of microbicides
unlike first generation; known biological responses
between virus and drugs, anti-HIV specific in small mole-
cules, developing different combinations microbicides
specifically designed to be active against HIV as well as
combination therapies holding promises of even greater
protection against HIV transmission than earlier formula-
tions, pharmaceutical industries should develop a wide
range of formulations currently being taken by people liv-
ing with HIV/Aids-(PLWHAS) Microbicides are self-
administered tropical substances that can block transmis-
sion of HIV and sexually transmitted infections, produced
in various forms such as gel creams, sponges, lubricants
and intravaginal rings applied inside the vagina or rectum.
Those formulated using ARVs target the cells it infects.
Some of these drugs stop HIV from binding a persons
CD4 receptor of target cell a critical processes enabling
virus replicate. Currently, a microbicide get formulated
using tenofovirone of key 'ARVs used in HIV/Aids treat-
ment.
Focus now is on dosage and form in which these microbi-
cides will be delivered. Will it be once or twice a day, or
come in form of gels, intravaginal rings or virginal tables?
And can any form be applied by a woman during or after
sexual intercourse. A lot of product acceptability studies
are going on across sub-Sahara African countries, where
over 75 per cent of microbicide studies are being con-
ducted. Efforts to ensure the tools are acceptable to
women do not irritate or offend their male partners are
underway. Microbicides is one in the cocktail of tools
including female condoms which are seen as the best way
of empowering women to protecting themselves from
HIV infection, especially when engaging in unprotected
sex. Since utilization of the female condom remains low.
Challenge facing most microbicides developers is how to
make those that will turn out to be effective, accessible
and affordable to women who need them most.
Community members provide valuable insight into cul-
tural contexts where trails are going to take place; hence
need to be consulted prior to commencing research.
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